Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6334

Provisional Schedule

Committee meeting 05 November 2024
Expected publication 28 January 2025

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ

Stakeholders

Companies sponsors Takeda UK (brentuximab vedotin)
Others Department of Health and Social Care
  NHS England
Patient carer groups Lymphoma Action
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups None
Comparator companies Accord Healthcare Limited (doxorubicin) (confidentiality agreement not signed, not participating)
  Hospira (vinblastine) (confidentiality agreement not signed, not participating)
  Janssen-Cilag Ltd (doxorubicin) (confidentiality agreement not signed, not participating)
  Kyowa Kirin Ltd (bleomycin) (confidentiality agreement not signed, not participating)
  Medac GmbH (dacarbazine, doxorubicin) (confidentiality agreement not signed, not participating)
  Pfizer Limited (doxorubicin) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals Ltd (doxorubicin) (confidentiality agreement not signed, not participating)
  Teva Pharma B.V. (doxorubicin) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
05 July 2024 Following a regulatory update from the company, the Committee meeting will now take place on 5 November 2024.
02 February 2024 Invitation to participate
29 November 2023 - 09 January 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 November 2023 In progress. Appraisal in progress.
06 October 2023 For information, please see draft timelines. This evaluation is expected to start during late November 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the evaluation during early-February 2024. Please note this evaluation will include a review of TA594 which originally published in August 2019.
11 September 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
11 September 2023 Topic selection
22 August 2023 This evaluation will include a review of TA594 published August 2019
20 July 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual